SOM230 combined with celecoxib prolongs the survival in nude mice with HepG-2 xenografts

被引:14
作者
Xie, Yan [1 ]
Chen, Shuang [2 ]
Wang, Chun-hui [1 ]
Tang, Cheng-wei [1 ,2 ]
机构
[1] W China Hosp, W China Sch Med, Dept Gastroenterol, Chengdu, Peoples R China
[2] Sichuan Univ, Div Peptides Related Human Dis, State Key Lab Biotherapy, Chengdu 610064, Peoples R China
关键词
HCC; SOM230; somatostatin analogue; celecoxib; COX-2; necrosis; xenografts; ENDOTHELIAL GROWTH-FACTOR; ADVANCED HEPATOCELLULAR-CARCINOMA; LONG-ACTING OCTREOTIDE; TUMOR ANGIOGENESIS; IN-VIVO; CYCLOOXYGENASE-2; PATHWAY; SOMATOSTATIN ANALOGS; SYSTEMIC THERAPY; EXPRESSION; INHIBITION;
D O I
10.4161/cbt.12.1.15730
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
A new non-cytotoxic therapy that SOM230 (pasireotide), a somatostatin analogue (SS TA) combined with celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor was tested in nude mice bearing HepG2 xenografts. Two agents did not markedly arrest the growth of HepG2 cells but greatly downregulated vascular endothelial growth factor expression. An imbalance between the vigorous demand and insufficient supply of nutrients and oxygen for tumor growth resulted in the massive necrosis of xenografts. The combination synergistically induced the early apoptosis of HepG2 cells and achieved longest survival without adverse reaction. This impressive strategy appears promising as a systemic therapy for patients with hepatocellular carcinoma (HCC).
引用
收藏
页码:86 / 92
页数:7
相关论文
共 42 条
  • [1] Direct evidence for endothelial vascular endothelial growth factor receptor-1 function in nitric oxide-mediated angiogenesis
    Ahmad, Shakil
    Hewett, Peter W.
    Wang, Ping
    Al-Ani, Bahjat
    Cudmore, Melissa
    Fujisawa, Takeshi
    Haigh, Jody J.
    le Noble, Ferdinand
    Wang, Ling
    Mukhopadhyay, Debabrata
    Ahmed, Asif
    [J]. CIRCULATION RESEARCH, 2006, 99 (07) : 715 - 722
  • [2] Cyclooxygenase inhibitors induce the expression of the tumor suppressor gene EGR-1, which results in the up-regulation of NAG-1, an antitumorigenic protein
    Baek, SJ
    Kim, JS
    Moore, SM
    Lee, SH
    Martinez, J
    Eling, TE
    [J]. MOLECULAR PHARMACOLOGY, 2005, 67 (02) : 356 - 364
  • [3] Long-acting octreotide versus placebo for treatment of advanced HCC:: A randomized controlled double-blind study
    Becker, Gerhild
    Allgaier, Hans-Peter
    Olschewski, Manfred
    Zaehringer, Andreas
    Blum, Hubert Erich
    [J]. HEPATOLOGY, 2007, 45 (01) : 9 - 15
  • [4] Cyclooxygenase-2 (COX-2) - A therapeutic target in liver cancer?
    Breinig, Marco
    Schirmacher, Peter
    Kern, Michael Andre
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2007, 13 (32) : 3305 - 3315
  • [5] SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile
    Bruns, C
    Lewis, I
    Briner, U
    Meno-Tetang, G
    Weckbecker, G
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2002, 146 (05) : 707 - 716
  • [6] Hepatocellular Carcinoma: Current Management
    Cha, Charles H.
    Saif, M. Wasif
    Yamane, Brett H.
    Weber, Sharon M.
    [J]. CURRENT PROBLEMS IN SURGERY, 2010, 47 (01) : 10 - 67
  • [7] Cheng ASL, 2004, INT J ONCOL, V24, P853
  • [8] Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies
    Chou, Ting-Chao
    [J]. PHARMACOLOGICAL REVIEWS, 2006, 58 (03) : 621 - 681
  • [9] Vitro and in vivo effects and mechanisms of celecoxib-induced growth inhibition of human hepatocellular carcinoma cells
    Cui, W
    Yu, CH
    Hu, KQ
    [J]. CLINICAL CANCER RESEARCH, 2005, 11 (22) : 8213 - 8221
  • [10] Danesi R, 1997, CLIN CANCER RES, V3, P265